Department of Neurology, St. John's Hospital, Medical faculty, Sigmund Freud University Vienna, Wien, Austria.
Department of Neurology, Helsinki University Hospital, Helsinki, Finland.
Acta Neurol Scand. 2018 Jan;137(1):105-108. doi: 10.1111/ane.12817. Epub 2017 Sep 4.
Beta-blocker therapy has been suggested to have neuroprotective properties in the setting of acute stroke; however, the evidence is weak and contradictory. We aimed to examine the effects of pre-admission therapy with beta-blockers (BB) on the mortality following spontaneous intracerebral hemorrhage (ICH).
Retrospective analysis of the Helsinki ICH Study database.
A total of 1013 patients with ICH were included in the analysis. Patients taking BB were significantly older, had a higher premorbid mRS score, had more DNR orders, and more comorbidities as atrial fibrillation, hypertension, diabetes mellitus, ischemic heart disease, and heart failure. After adjustment for age, pre-existing comorbidities, and prior use of antithrombotic and antihypertensive medications, no differences in in-hospital mortality (OR 1.1, 95% CI 0.8-1.7), 12-month mortality (OR 1.3, 95% CI 0.9-1.9), and 3-month mortality (OR 1.2, 95% CI 0.8-1.7) emerged.
Pre-admission use of BB was not associated with mortality after ICH.
在急性卒中的情况下，β受体阻滞剂治疗被认为具有神经保护作用；然而，证据薄弱且相互矛盾。我们旨在研究β受体阻滞剂（BB）在自发性脑出血（ICH）后死亡率的影响。
对赫尔辛基 ICH 研究数据库进行回顾性分析。
共纳入 1013 例 ICH 患者。服用 BB 的患者年龄明显较大，发病前 mRS 评分较高，有更多的 DNR 医嘱，并且合并症更多，如心房颤动、高血压、糖尿病、缺血性心脏病和心力衰竭。在调整年龄、既往合并症以及抗血栓和降压药物的使用后，住院死亡率（OR 1.1，95%CI 0.8-1.7）、12 个月死亡率（OR 1.3，95%CI 0.9-1.9）和 3 个月死亡率（OR 1.2，95%CI 0.8-1.7）没有差异。
ICH 前使用 BB 与死亡率无关。
